Search Results

Ancora Heart, Inc. and egnite, Inc. today announced a strategic partnership to accelerate clinical trial enrollment for Ancora Heart’s CORCINCH-HF pivotal clinical trial, which is evaluating the safety and efficacy of the AccuCinch® Ventricular Restoration System.

Ancora Heart, Inc today announced that patients treated with the investigational AccuCinch ® Ventricular Restoration System demonstrated improvement in HF patient outcomes and beneficial changes in the structure of the heart.

Ancora Heart, Inc. , a company developing a novel device-based therapy to address heart failure (HF), today announced that David J. Tucker has joined the company as chief financial officer.

Ancora Heart, Inc. today announced that a late-breaking clinical science presentation featuring the latest data from studies of the investigational AccuCinch ® Ventricular Restoration System will take place at the upcoming Technology and Heart Failure Therapeutics conference (THT 2023).

Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch ® Ventricular Restoration System.

Ancora Heart, Inc. a company developing a novel device-based therapy to address heart failure (HF), today announced that Mark Miles has joined the company as Chief Commercial Officer (CCO).

Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), has entered a term sheet to acquire Ancora Medical Inc. (“Ancora”), a privately held medical technology company with anchoring catheter and needle combo technology that was approved by the FDA in February 2020.

Ancora Heart AccuCinch ® System Shows Positive 12-Month Outcomes in Multi-Study Analysis